World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Alzheimer's disease and other dementias
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To define a practice guideline for biological treatment of dementia and to make transparent the development of the guideline connecting the original data with the resulting recommendations. METHODS: This guideline includes pharmacologic treatment considerations for patients with Alzheimer's disease, vascular dementia, DLB, and fronto-temporal dementia. Studies were selected that represent double-blind placebo-controlled trials of at least 3 months duration in patients with a diagnosis of dementia according to accepted international diagnostic criteria (for example the NINCDS/ADRDA or NINDS/AIREN criteria). Moreover, to be included studies had to fulfill a restrictive set of methodological criteria. Original studies and not meta-analyses determined the evaluation and the development of recommendations. RESULTS: Antidementia pharmaceuticals neither cure nor arrest the disease. A modest effect of improvement of symptoms compared with placebo can be observed. Antidementia pharmaceuticals show different efficacy and side effect profiles. The type of dementia, the individual symptom constellation and the tolerability should determine what medication should be used. There are hints that combination therapy of drugs with different therapeutic mechanisms might improve the efficacy. In treating neuropsychiatric symptoms (NPS), psychosocial intervention should be the treatment of first choice. Pharmaceuticals can only be recommended when psychosocial interventions is not adequate. However, even then the side effects of pharmaceuticals limit their use. CONCLUSIONS: Depending on the diagnostic entity and the pathology treated different anti-dementia drugs can be recommended to improve symptoms. In the management of NPS, side effects limit the use of medications even when psychosocial interventions have failed. Thus, there is an urgent need to develop more efficacious medications for the treatment of dementia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Self-citationRomán, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J.-M., Brun, A., Hofman, A., et al. (1993) · Neurology · doi:10.1212/wnl.43.2.250 · Cited by 4,921
. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186
The clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Petersen, R. C., Stevens, J. C., Ganguli, M., Tangalos, E. G., Cummings, J. L., & DeKosky, S. T. (2001) · Neurology · doi:10.1212/wnl.56.9.1133 · Cited by 2,065
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Improving the reporting of pragmatic trials: An extension of the CONSORT statement
Zwarenstein, M., Treweek, S., Gagnier, J. J., Altman, D. G., Tunis, S., Haynes, B., Oxman, A. D., Moher, D., & groups, F. T. C. A. P. T. I. H. (. (2008) · BMJ · doi:10.1136/bmj.a2390 · Cited by 1,813
Meta-Analysis: Recent Developments in Quantitative Methods for Literature Reviews
Rosenthal, R., & DiMatteo, M. R. (2001) · Annual Review of Psychology · doi:10.1146/annurev.psych.52.1.59 · Cited by 1,780
Moher, D., Schulz, K. F., Altman, D. G., & for the CONSORT Group* (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00011 · Cited by 1,426
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“However, there is an opinion that the brain may be cleaned of plaques but the disease remains unchanged (Holmes et al. 2008).”
BackgroundEffectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease
Schneider, L. S., Tariot, P. N., Dagerman, K. S., Davis, S. M., Hsiao, J. K., Ismail, M. S., Lebowitz, B. D., Lyketsos, C. G., Ryan, J. M., Stroup, T. S., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061240 · Cited by 1,206 · cited 2×
“Nevertheless, neuroleptics are accompanied by a high rate of side effects possibly including an increased mortality rate (Haddad and Dursun 2008; Schneider et al. 2006; Sultzer et al. 2008).”
BackgroundSelf-citationMcKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Le Bars, P. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160047037 · Cited by 966
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
Sink, K. M., Holden, K. F., & Yaffe, K. (2005) · JAMA · doi:10.1001/jama.293.5.596 · Cited by 910
The scandal of poor medical research.
Altman, D. G. (1994) · BMJ · doi:10.1136/bmj.308.6924.283 · Cited by 897
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Mild cognitive impairment in the elderly: Predictors of dementia
Flicker, C., Ferris, S. H., & Reisberg, B. (1991) · Neurology · doi:10.1212/wnl.41.7.1006 · Cited by 838
Erkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Agitated Behaviors in the Elderly: I. A Conceptual Review
Cohen‐Mansfield, J., & Billig, N. (1986) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1986.tb04302.x · Cited by 717
Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis
Fergusson, D., Aaron, S. D., Guyatt, G., & Hébert, P. (2002) · BMJ · doi:10.1136/bmj.325.7365.652 · Cited by 708 · cited 1×
“The advantages of ITT over OC analyses have been well explained (Fergusson et al. 2002), however, the LOCF method to replace Moreover, the length of the test varies between 11 and 13 items also infl uencing results.”
MethodTierney, M. C., Fisher, R. H., Lewis, A. J., Zorzitto, M. L., Snow, W. G., Reid, D. W., & Nieuwstraten, P. (1988) · Neurology · doi:10.1212/wnl.38.3.359 · Cited by 613
Livingston, G., Johnston, K., Katona, C., Paton, J., Lyketsos, C. G., & Old Age Task Force of the World Federation of Biological Psychiatry (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.1996 · Cited by 591 · cited 1×
“Nevertheless, several studies investigated these aspects (see Livingston et al. 2005; O ’ Connor et al. 2009a,b; Gauthier et al. 2010, for reviews).”
BackgroundMild cognitive impairment: Long-term course of four clinical subtypes
Busse, A., Hensel, A., Gühne, U., Angermeyer, M. C., & Riedel-Heller, S. G. (2006) · Neurology · doi:10.1212/01.wnl.0000249117.23318.e1 · Cited by 561 · cited 1×
“With the exception of multiple-domain non-amnestic MCI, all other MCI subtypes showed the highest association with AD in a population based study (Busse et al. 2006).”
BackgroundThe overlap between neurodegenerative and vascular factors in the pathogenesis of dementia
Iadecola, C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0718-6 · Cited by 557 · cited 1×
“Vice versa cerebrovascular dysfunction might aggravate the deleterious effects of AD (Iadecola, 2010).”
BackgroundOrgogozo, J.-M., Rigaud, A.-S., Stöffler, A., Möbius, H.-J., & Forette, F. (2002) · Stroke · doi:10.1161/01.str.0000020094.08790.49 · Cited by 539
Rivastigmine for Alzheimer’s disease.
Birks, J. S., Chong, L.-Y., & Grimley Evans, J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001191.pub4 · Cited by 534
CONSORT for reporting randomised trials in journal and conference abstracts
Hopewell, S., Clarke, M., Moher, D., Wager, E., Middleton, P., Altman, D. G., & Schulz, K. F. (2008) · The Lancet · doi:10.1016/s0140-6736(07)61835-2 · Cited by 458 · cited 1×
“Thus, improving the quality of reports has been recommended (Hopewell et al. 2008; Zwarenstein et al. 2009).”
BackgroundEfficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.54 · Cited by 422 · cited 1×
“Starting with an observational study in two patients with positive outcome (Leibovici and Tariot 1988) a preliminary study underlined the results (Tariot et al. 1994) that fi nally were supported in a randomized clinical trial (Tariot et al. 1998).”
Result(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Donepezil in vascular dementia: A randomized, placebo-controlled study
Wilkinson, D., Doody, R., Helme, R., Taubman, K., Mintzer, J., Kertesz, A., Pratt, R. D., & the Donepezil 308 Study Group* (2003) · Neurology · doi:10.1212/01.wnl.0000078943.50032.fc · Cited by 392
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386
Self-citationWilcock, G., M??bius, H. J., & St??ffler, A. (2002) · International Clinical Psychopharmacology · doi:10.1097/00004850-200211000-00005 · Cited by 381
Nyth, A. L., & Gottfries, C. G. (1990) · British Journal of Psychiatry · doi:10.1192/bjp.157.6.894 · Cited by 379 · cited 1×
“For citalopram, effi cacy is reported (Nyth and Gottfries 1990; Nyth et al. 1992) and it is recommended in the review of Herrmann and Lanct ô t (2007).”
MethodPollock, B. G., Mulsant, B. H., Rosen, J., Sweet, R. A., Mazumdar, S., Bharucha, A., Marin, R., Jacob, N. J., Huber, K. A., Kastango, K. B., et al. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.460 · Cited by 327
Sultzer, D. L., Davis, S. M., Tariot, P. N., Dagerman, K. S., Lebowitz, B. D., Lyketsos, C. G., Rosenheck, R. A., Hsiao, J. K., Lieberman, J. A., Schneider, L. S., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.07111779 · Cited by 321
Self-citationClark, C. M. (1999) · Archives of Neurology · doi:10.1001/archneur.56.7.857 · Cited by 298
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Nyth, A. L., Gottfries, C. G., Lyby, K., Smedegaard‐Andersen, L., Gylding‐Sabroe, J., Kristensen, M., Refsum, H. ‐., Öfsti, E., Eriksson, S., & Syversen, S. (1992) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1992.tb03242.x · Cited by 258
Pollock, B. G., Mulsant, B. H., Rosen, J., Mazumdar, S., Blakesley, R. E., Houck, P. R., & Huber, K. A. (2007) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3180cc1ff5 · Cited by 257 · cited 1×
“For effi cacy of cipramil as an alternative treatment, an indication can be found (Pollock et al. 2002, 2007).”
BackgroundSertraline for the treatment of depression in Alzheimer disease
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c796eb · Cited by 250 · cited 1×
“For fl uoxetine and sertraline, studies could not demonstrate effi cacy (Auchus and Bissey-Black 1997; Petracca et al. 2001; Magai et al. 2000; Rosenberg et al. 2010; Weintraub et al. 2010).”
BackgroundSelf-citationO'Connor, D. W., Ames, D., Gardner, B., & King, M. (2009) · International Psychogeriatrics · doi:10.1017/s1041610208007588 · Cited by 239
What errors do peer reviewers detect, and does training improve their ability to detect them?
Schroter, S., Black, N., Evans, S., Godlee, F., Osorio, L., & Smith, R. (2008) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2008.080062 · Cited by 226 · cited 1×
“However, reviewers do not detect the failures, even with training (Schroter et al. 2008).”
BackgroundGauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1949 · Cited by 220
Román, G. C., Salloway, S., Black, S. E., Royall, D. R., DeCarli, C., Weiner, M. W., Moline, M., Kumar, D., Schindler, R., & Posner, H. (2010) · Stroke · doi:10.1161/strokeaha.109.570077 · Cited by 161
Magai, C., Kennedy, G., Cohen, C. I., & Gomberg, D. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200002000-00009 · Cited by 143
Yancheva, S., Ihl, R., Nikolova, G., Panayotov, P., Schlaefke, S., Hoerr, R., & for the GINDON Study Group (2009) · Aging & Mental Health · doi:10.1080/13607860902749057 · Cited by 127
Self-citationO'Connor, D. W., Ames, D., Gardner, B., & King, M. (2009) · International Psychogeriatrics · doi:10.1017/s1041610208008223 · Cited by 126
Clark, W. S., Street, J. S., Feldman, P. D., & Breier, A. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0108 · Cited by 101
Gutzmann, H., Kühl, K.-P., Hadler, D., & Rapp, M. A. (2002) · Pharmacopsychiatry · doi:10.1055/s-2002-19833 · Cited by 85
Cited by
Management of mild cognitive impairment (MCI): The need for national and international guidelines
Kasper, S., Bancher, C., Eckert, A., Förstl, H., Frölich, L., Hort, J., Korczyn, A. D., Kressig, R. W., Levin, O., & Palomo, M. S. M. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1696473 · Cited by 233
“EGb 761R has demonstrated efficacy in the cognitive function and neuropsychiatric symptoms of patients with AD, vascular and mixed dementia comparable to that of AChE-I or memantine, but with fewer side-effects (Ihl et al. 2011).”
BackgroundInfluentialSelf-citationCombination Drug Therapy for the Management of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093272 · Cited by 217
Effects of Ginkgo biloba on dementia: an overview of systematic reviews
Yuan, Q., Wang, C.-W., Shi, J., & Lin, Z.-X. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.12.005 · Cited by 148
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Metadata
- Authors
- Ihl, R., Frölich, L., Winblad, B., Schneider, L., Burns, A., Möller, H.-J., & WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias
- Venue
- The World Journal of Biological Psychiatry
- Publisher
- Informa UK Limited
- Published
- 2011-02
- Volume
- 12
- Issue
- 1
- Pages
- 2-32
- ISSN
- 1562-2975 (ISSN-L)
- 1814-1412
- OpenAlex
- W2152390559
- Cited by
- 97
- References
- 52
- FWCI
- 7.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.